Composition and method for treating neurological disease
US10512617B2 · kind B2 · utility
2Cited by
58References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2019 |
| Grant date | Dec 24, 2019 |
| Priority date | — |
| Expiry date | Jan 17, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.